Ukr.Biochem.J. 2018; Volume 90, Issue 4, Jul-Aug, pp. 111-114


Evaluation of serum adenosine deaminase and its isoenzymes in patients with ovarian cancer

A. Asadi1, S. M. Atyabi2, S. Sadeghi3, S. Khatami3,  M. Ebrahimi-Rad3, S. Valadbeigi3, R. Saghiri3

1Islamic Azad University North Tehran Branch, Tehran, Iran;
2Nanotechnology Department, Pasteur Institute of Iran, Tehran;
3Biochemistry Department, Pasteur Institute of Iran, Tehran;

Ovarian cancer is the most lethal gynecological cancer worldwide. There are great relationships between the activities of adenosine deaminase (ADA), one of the enzymes in purine nucleotide pathway and carcinogenic process.  In the present study the activities of the total ADA, ADA1 and ADA2 were measured in the sera of the patients with ovarian cancer. In this study, activities of tADA, ADA1 and ADA2 were assessed in sera of 30 patients with ovarian cancer and 30 normal control individuals, using a modified Ellis method in which only ADA2 activity was measured in the present of a specific inhibitor, erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA). Our results showed that the tADA, ADA1, and ADA2 serum activities of patients were found to be significantly increased (P < 0.05) than those of healthy control group. Although, ADA and its isoenzymes were not the specific markers for diagnosis of ovarian cancer, measurement of their activities may be used as a diagnostic means in ovarian cancer as well as the other analytical procedures.

Keywords: , , ,


  1. Reynolds EA, Moller KA. A review and an update on the screening of epithelial ovarian cancer. Curr Probl Cancer. 2006 Sep-Oct;30(5):203-32. PubMed, CrossRef
  2. Urunsak IF, Gulec UK, Paydas S, Seydaoglu G, Guzel AB, Vardar MA. Adenosine deaminase activity in patients with ovarian neoplasms. Arch Gynecol Obstet. 2012 Jul;286(1):155-9. PubMed, CrossRef
  3. Rein BJ, Gupta S, Dada R, Safi J, Michener C, Agarwal A. Potential markers for detection and monitoring of ovarian cancer. J Oncol. 2011;2011:475983. PubMed, PubMedCentral, CrossRef
  4. Guppy AE, Nathan PD, Rustin GJ. Epithelial ovarian cancer: a review of current management. Clin Oncol. 2005 Sep;17(6):399-411. PubMed, CrossRef
  5.  Sharma S, Desai PB, Metgudmath RB. Evaluation of Serum Adenosine Deaminase and Retinol in patients with Laryngeal Cancer. Indian J Pharm Biol Res. 2013;1(4):30-34. CrossRef
  6. Ellis G, Goldberg DM. A reduced nicotinamide adenine dinucleotide–linked kinetic assay for adenosine deaminase activity. J Lab Clin Med. 1970 Sep;76(3):507-17. PubMed
  7. Goodarzi MT, Abdi M, Tavilani H, Nadi E, Rashidi M. Adenosine deaminase activity in COPD patients and healthy subjects. Iran J Allergy Asthma Immunol. 2010 Mar;9(1):7-12. PubMed
  8. Poursharifi P, Saghiri R, Ebrahimi-Rad M, Nazem H, Pourpak Z, Moin M, Shams S. Adenosine deaminase in patients with primary immunodeficiency syndromes: the analysis of serum ADA1 and ADA2 activities. Clin Biochem. 2009 Sep;42(13-14):1438-43.  PubMed, CrossRef
  9. Aldrich MB, Blackburn MR, Kellems RE. The importance of adenosine deaminase for lymphocyte development and function. Biochem Biophys Res Commun. 2000 Jun 7;272(2):311-5. PubMed, CrossRef
  10. Niedzwicki JG, Abernethy DR. Structure-activity relationship of ligands of human plasma adenosine deaminase2. Biochem Pharmacol. 1991 Jun 1;41(11):1615-24. PubMed, CrossRef
  11. Gakis C. Adenosine deaminase (ADA) isoenzymes ADA1 and ADA2: diagnostic and biological role. Eur Respir J. 1996 Apr;9(4):632-3. PubMed, CrossRef
  12. Ungerer JP, Oosthuizen HM, Bissbort SH, Vermaak WJ. Serum adenosine deaminase: isoenzymes and diagnostic application. Clin Chem. 1992 Jul;38(7):1322-6. PubMed
  13. Yildirim Z, Hasanoglu HC, Akyol O, Gokirmak M, Köksal N. Serum adenosine deaminase activities in lung cancer and mesothelioma. Clin Biochem. 1999 Jun;32(4):283-5. PubMed, CrossRef
  14. Canbolat O, Durak I, Cetin R, Kavutcu M, Demirci S, Oztürk S. Activities of adenosine deaminase, 5′-nucleotidase, guanase, and cytidine deaminase enzymes in cancerous and non-cancerous human breast tissues. Breast Cancer Res Treat. 1996;37(2):189-93. PubMed, CrossRef
  15. Aghaei M, Karami-Tehrani F, Salami S, Atri M. Adenosine deaminase activity in the serum and malignant tumors of breast cancer: the assessment of isoenzyme ADA1 and ADA2 activities. Clin Biochem. 2005 Oct;38(10):887-91. PubMed, CrossRef
  16. Canbolat O, Akyol O, Kavutcu M, Isik AU, Durak I. Serum adenosine deaminase and total superoxide dismutase activities before and after surgical removal of cancerous laryngeal tissue. J Laryngol Otol. 1994 Oct;108(10):849-51. PubMed, CrossRef
  17. Akyol Ö, Arslanoǧlu R, Durak İ. Activities of free radical and DNA turn-over enzymes in cancerous and non-cancerous human brain tissues. Redox Rep. 1995 Aug;1(4):255-9.   PubMed, CrossRef
  18. Pragathi P, Bharath Kumar PV, Amar Kumar P, Ramakanth Reddy M, Sravani V, Neeraja J, Reeba Mary E, Gopalakrishna K. Evaluation of serum adenosine deaminase and 5′-nucleotidase activities as probable markers in ovarian cancer. Indian J Clin Biochem. 2005 Jul;20(2):195-7.  PubMed, PubMedCentral, CrossRef

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.